An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in adults 60 years of age […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!